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Abstract
Hypertrophic scars represent important problems because of the presence of 
pain, pruritus, contractures, as well as unsatisfactory aesthetic results. Currently, 
the evidence shows that a multidisciplinary management through prevention, 
adequate choice of suture, atraumatic surgical technique, and early noninvasive 
measures can favor the handling of these problems and continue with invasive 
measures that employ intralesional drugs. Clearly, the combination of surgical, 
technical, and pharmacological interventions will maximize therapeutic results.
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1. Introduction
Hypertrophic scars (HS) are defined as a pathological scars that have abnormal 
thickness and are raised from the previous wound [1]. Such scars are the most 
common complication of burn injury and abnormal wound healing response after 
traumatic injury, surgery, or inflammation [2, 3]. These lesions are characterized 
by their red to purple color, raised appearance, decreased pliability, and tenderness 
with concomitant symptoms including pruritus and pain [4–9]. Patients with HS 
may suffer from stiffness, cosmetic disfigurement, joint contractures, as well as 
impediment in physical function and daily activities, and even psychological issues 
such as depression or anxiety [1, 10–12].
2. Epidemiology
The best clinical predictor for the development of hypertrophic burn scars is a 
prolonged inflammatory wound healing phase. This result usually corresponds with 
a wound that has not epithelialized and continues to exudate for more than 3 weeks 
[13]. Hypertrophic scars generally develop at about 2 months after a burn and will 
continue to proliferate for a year or longer. HS maturation may not occur until 18 or 
even 24 months after a burn. The exact time point of regression or maturation of HS 
remains unknown [8–10, 14, 15].
According to the literature, about 32–72% of surgical skin wounds result in HS 
after 1 year [16, 17]. In Asian, the prevalence rate of HS after burn injury is as high 
as 70%, much higher than in Caucasian populations. Contractures after burns have 
a prevalence of 38–54% of patients, with up to 46% patients undergoing at least one 
reconstructive procedure after their acute hospital stays [18, 19] (Figure 1).
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In order to prevent and treat pathologic wounds, one must first understand the 
basics of normal wound healing.
3. Wound healing
The desirable result of normal wound healing is replacement of the initial hemo-
static clot with skin that approximates the aesthetic, mechanical, and functional 
properties of the preinjury tissue.
Historically, wound healing has been arbitrarily divided into three phases, with 
some authors adding hemostasis as the inciting phase. Although wound healing 
occurs on a time continuum, division of the process into phases allows for ease of 
description and evaluation. Changes in the steps of normal wound healing may 
result in either a “hypoplastic” or chronic nonhealing wound or a hypertrophic 
“over-healed” wound [20].
The clotting cascade is activated immediately after trauma, a consequence of 
the disruption of the vascular endothelium and exposure of the basal lamina that 
results in extravasation of blood constituents and concurrent platelet activation. 
Subsequently, the release of growth factors causes the deposition of extracellular 
matrix (transforming growth factor β), chemotaxis (platelet-derived growth fac-
tor), epithelialization (fibroblast growth factor and epidermal growth factor), and 
angiogenesis (vascular endothelial growth factor) [21, 22].
4. Inflammatory
An inflammatory phase develops and persists for 4–6 days. This phase is character-
ized by hemostasis and leukocytic infiltration led by polymorphonuclear leukocytes. 
Neutrophils, as well as monocytes, fibroblasts, and endothelial cells deposit on a fibrin 
scaffold formed by platelet activation. The presence of neutrophils is followed closely 
by monocytes that are quickly activated into tissue macrophages. These cells cause 
further tissue debridement and secrete additional cytokines as well as growth factors 
that promote fibroblast proliferation, angiogenesis, and keratinocyte migration [23].
5. Proliferative
The proliferative phase of wound healing begins at 4 days and persists up to 
14 days; this phase is heralded by the transformation of monocytes to macrophages. 
Figure 1. 
Patient with a history of flame burn. Hypertrophic scars that affect the first interdigital space.
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Keratinocytes initiate epithelialization and are present on the wound edge as well 
as from dermal appendages such as hair follicles, sweat, and sebaceous glands. 
Epidermal growth factor, fibroblast growth factor, transforming growth factor 
β, and multiple cytokines originate cell detachment and mitotic division; then, 
fibroblasts appear in the wound after 24 hours of this stimulation and produce 
collagen. This process requires adequate oxygen supply. In fact, without oxygen to 
assist in the hydroxylation of proline and lysine residues, chemical bonds will not 
form appropriately to create a mature form of collagen. These bonds are very criti-
cal because their absence can prolong the stage and result in a chronic wound. They 
serve as the basis for the final stage of maturation and remodeling [24].
6. Maturation
Appropriate wound maturation and remodeling result in a quickly healed and 
minimally visible scar; whereas, prolongation or deviations from this phase can 
cause hypertrophic, keloid scars or chronic nonhealing wounds. This initial collagen 
is thinner than uninjured. Type III collagen initially comprises 30% of the granula-
tion tissue matrix, compared with 10–20% in uninjured skin. Over time, the ratio 
of type III collagen decreases, and type I collagen increases. An overall increase in 
collagen formation is seen for 4–5 weeks; after this time wound strength increases 
and parallels the increase in type I collagen [25, 26].
7. Cellular basis, signals and pathways of hypertrophic scars
Fibroblasts and myofibroblasts are pivotal effectors cells in HS [27]. The activa-
tion of fibroblasts and differentiation into myofibroblasts (that are a phenotypi-
cally intermediate cell type between fibroblasts and smooth muscle cells) are the 
central processes in the pathophysiology of hypertrophic scars. The larger the area 
of the wound, the greater migration of myofibroblasts. This situation results in 
more prominent scarring [28, 29]. Many origins of fibroblasts or myofibroblasts 
have been characterized: local dermis and subcutaneous tissues around the wound 
Figure 2. 
Activation of fibroblasts and differentiation into myofibroblasts are the central processes in the pathophysiology 
of hypertrophic scars.
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site, pericytes and vascular smooth muscle cells, tubular epithelial cells through 
epithelial-mesenchymal transition (EMT), tissue specific stem cells, and bone 
marrow-derived peripheral blood fibrocytes (Figure 2) [30].
The proliferative fibroblasts produce massive collagen and make extracellular 
matrix (ECM) that accumulates below the dermis. One sign thought to be of par-
ticular importance is that transforming growth factor-beta (TGF-b), acting through 
a signaling pathway in fibroblasts, appears to cause an increase in production of 
ECM and leads to cellular proliferation [31, 32]. Over time, some cells can develop 
autocrine TGF-b positive feedback loops that can lead to a self-propagating cycle of 
excessive extracellular matrix production and cell proliferation. Moreover, fibro-
blasts infiltrate and degrade the fibrin clot by producing matrix metalloproteinases 
(MMPs) and tissue inhibitor of metalloproteinases (TIMPs). This action results in 
an imbalance between the formation and degradation of matrix [33].
8. Risk factors
Risk factors for the development of pathologic scarring in the setting of burns 
have been reported to include darker skin color [1, 34], female sex [35], young age 
[17, 35, 36], allergy [16, 37], bacterial colonization [38], stretch and burns to the 
neck or upper limb [35], multiple surgical procedures [35], meshed skin graft [35], 
increased time to healing [1, 35, 38, 39], and burn depth [35].
Factors that reduce the risk of presenting HS are: chemotherapy [40], smoking [17], 
statins [41], and genetic background that does not have association [42] (Table 1).
9. Genetic
No convincing evidence exists for a familial pattern in patients who suffer from 
HS. In a systematic review, the authors did not find any pedigree studies on HS [42, 43].
10. Dark skin
In the literature, dark skin has a higher incidence of HS compared with lighter 
skin of Caucasians. Dark skin contains more and larger fibroblasts that deposit 
more collagen, related to what was previously written [1, 34, 36].
Increase HS
Darker skin color Stretch
Female sex Neck and upper limb
Young age Multiple surgical procedures
Allergy Meshed skin graft
Bacterial colonization Increased time healing
Burn depth
Decrease HS
Chemotherapy
Smoking
Statins
Table 1. 
Overview of factors associated with the development and reduce risk of HS described by other authors to date.
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11. Female sex
Gangemi and colleagues observed in a multivariate regression model that 
female sex, young age, burn sites on the neck and/or upper limbs, multiple surgi-
cal procedures, and meshed skin grafts were risk factors for postburn pathologic 
scarring [35].
12. Age
Evidence supports the negative association of age with HS. Excessive scars 
develop mostly in younger patients between 11 and 30 years old. The inflammatory 
response decreases with age: epidermal turnover is slower in elderly individuals, 
and the epidermis contains fewer cells [17, 35, 36, 44].
13. Allergy
Hypothesize that increased degranulation of mast cells observed in allergic 
individuals supports HS formation. This relationship of allergy with HS formation 
is supported by level III evidence [16, 37].
14. Bacterial colonization
Bacterial toxins stimulate and prolong the inflammatory phase of wound healing 
and, thereby stimulate HS [38, 45].
15. Evaluation of hypertrophic scar
Currently no standardized system method exists to assess postsurgical scars. 
In the literature, scar assessment has mainly been focused on burn scars, but an 
increasing interest in postsurgical scars is seen, both to evaluate postoperatively as 
well as to have a closer and objective monitoring when therapeutic measures are 
applied so as to conclude whether the management is effective or, on the contrary 
worsening the situation of the scar [4, 9].
Comprehensive scar assessment must include three different dimensions: (a) 
physical characteristics; (b) cosmetic appearance; and (c) patient’s symptoms 
(Table 2).
To date, only four scales have been psychometrically studied: the Vancouver 
Scar Scale (VSS), the Patient and Observer Scar Assessment Scale (POSAS), the 
Manchester Scar Scale (MSS), and the Stony Brook Scar Evaluation Scale (SBSES) 
(Table 3).
Scar assessment
Physical characteristics
Cosmetic appearance
Symptoms
Table 2. 
Points to scar assessment.
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16. Vancouver scar scale (VSS)
The VSS was created in 1990 and is the most widely used rating scale for scars. 
Four physical characteristics are scored: height, pliability, vascularity, and pigmen-
tation. Each variable is ranked to obtain a total score ranging from 0 to 13, with 0 
representing normal skin [46, 47] (Table 4).
17. Manchester scar scale
The MSS includes six items: contour, texture, color, distortion, shiny surface, 
and overall patient’s opinion [47].
18. Patient and observer scar assessment scale
The POSAS is a recent and promising scar assessment tool that incorporates both 
observer and patient scar ratings [47, 48].
Scar scales
Vancouver scar scale
Patient and observer scar assessment scale
Manchester scar scale
Stony Brook scar evaluation scale
Table 3. 
Scales psychometrically studied for the evaluation of scars.
Table 4. 
Vancouver scar scale.
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19. Stony Brook scar evaluation scale
Scars are assigned 0–1 point for the presence or absence of the following: width 
greater than 2 mm at any point of the scar, raised (or depressed) scar, and darker 
coloration than surrounding skin. The total score is then derived from the scale and 
ranges from 0 (worst) to 5 (best) [47, 49].
20. Treatment of hypertrophic scar
Different methods have been described for the treatment of hypertrophic scars. 
Among those have been found prevention, re-excision with primary closure, mas-
sages, compression clothes, silicone sheets, intralesional injections, laser therapy 
and topical treatments (Table 5).
21. Prevention
The prevention is the conjunction of measures that reduce inflammation and 
provide rapid wound closure such as early debridement of dead space, reducing the 
risk of infection through rinsing and disinfection, as well as optimal dressings that 
provide moist wound healing and/or early surgical wound coverage. During the 
operation, the surgeon should also use adequate sutures and avoid excessive ten-
sion. Surgical closure must be meticulous with an atraumatic technique to generate 
a successful and minimal linear scar. In the training of plastic surgery, the use of 
fine and atraumatic instruments is taught for the handling of the tissues for example 
hooks for retraction. Without a doubt, the tension found in the closure of a wound 
plays a very important role in widened and hypertrophic scars; these tension forces 
separate the edges of the wound and generate a wider scar with time. This result can 
be decreased with the liberation and advancement of the edges, in addition to the 
placement of correct subdermal sutures [50].
Once the wound has been prepared and is ready for closure, the proper suture 
and suture technique must be selected. Wounds may be closed with simple inter-
rupted, horizontal mattress, vertical mattress, figure-of-eight, or running sutures. 
The choice of the suture is of great importance, and most of the time despised, 
attention should be paid to the estimated time to resorption since the suture may 
or may not provide adequate support during the healing process. With a Level II 
Treatment of hypertrophic scar
No invasive
Prevention
Pressure garment therapy
Scar massage
Laser therapy
Silicone gel sheeting
Invasive
Triamcinolone acetonide
5-Fluorouracil
Table 5. 
Treatment of hypertrophic scars.
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of Therapeutic Evidence, polydioxanone (PDS) has been found to result in less 
scar widening and less scar hypertrophy at 6 months compared with polyglycolic 
acid (PGA). In the first 3 weeks of wound healing, the strength of a wound is only 
a small fraction of its eventual strength. Sutures removed or degraded before this 
time have little effect in preventing wound spreading. Polyglactic acid suture loses 
strength after 3 weeks, at which time the wound is still relatively weak. These 
results are similar to removing a nylon suture from the wound in 1 week [51, 52].
Leaving a permanent intradermal suture in place for several months has been 
shown to decrease spreading, and a synthetic suture possibly retains strength for 
6–8 weeks and may have the same effect. This result is caused by the difference in 
the absorption time and what comes from the loss of tensile strength. On an average 
PGA scars were wider than PDS scars by 33% (means 9.6, 7.2), the difference that 
was statistically highly significant (Wilcoxon test p < 0.001) [51, 52].
In another study that used the Vancouver Scar Scale (VSS), the scar’s width and 
quality of polydioxanone (PDS) was compared with that of polyglactin 910. The 
scars were evaluated at 1, 3 and 4 months postoperatively. On follow-up, the mean 
scar width in Polyglactin 910 was significantly more than that of PDS. The VSS 
score was significantly lower in the PDS group at the third and fourth month follow 
up and signified better scar quality [53].
22. Noninvasive measures
22.1 Pressure garment therapy (PGT)
The theory behind the use of PGT may be quite simple and relies on two main 
concepts; first, the restriction of blood flow to the scar area inhibits the growth 
of hypertrophic scar tissue and second constant compression does too [54]. Some 
evidence indicates that PGT may have an effect on the remodeling of hypertrophic 
burn scar elements such as fibrillin and elastin [55]. In an experimental model with 
swine that received pressure treatment with a device mounting and delivery at 
30 mm Hg of constant pressure for 2 weeks, the total collagen quantification using 
hydroxyproline assay showed a 51.9% decrease after pressure initiation. Pressure 
treated scars also had lower levels of collagen I and III after pressure treatment 
(P < 0.05) compared with sham and untreated scars [56]. Using a newly developed 
pressure therapy system, the Smart Pressure Monitored Suits. Pre and post treat-
ment comparison demonstrated significant improvement in scar pigmentation, 
thickness, VSS scores, as well as scores of pain and itch (p < 0.01) for the early 
intervention group prescribed within 60 days after injuries compared with the late 
intervention group prescribed after 61 days. The early group demonstrated superior 
effect in improving scar lightness, yellowness (p < 0.01), thickness (p < 0.01), 
pigmentation score (p < 0.05) and pain score (p < 0.01) than the late group in 
comparison between the two groups at similar postburn timing [57].
However, a meta-analysis of clinical results suggests that PGT does not appear to 
alter global scar scores, but does appear to improve scar height, although this differ-
ence is small and of questionable clinical importance. The beneficial effects of PGT 
remain unproven while the potential morbidity and cost are not insignificant [58].
22.2 Scar massage
Scar massage is used in burn units globally to improve functional and cosmetic 
outcomes of hypertrophic scarring following a burn; however, the evidence to sup-
port this therapy is unknown [59].
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22.3 Laser therapy
The three main groups of lasers that can be used to improve scars include pulsed 
dye lasers (PDLs), Nd:YAG lasers, as well as ablative and nonablative fractional 
lasers.
A systematic review of the effectiveness of the ablative 10,600 nm CO2 laser, 
shows objective improvement in scar color, thickness, and sensation, but not in 
scar elasticity. All studies reported improvements in the mean total VSS score and/
or VSS component scores (pliability, height, vascularity, pigmentation), without 
statistically significant differences between raters. Statistically significant improve-
ments in both the patient and the observer sections of the POSAS were reported 
after CO2 laser treatment. Despite these positive findings, all studies were of low 
or unclear quality. As a result, insufficient scientific evidence exists to determine 
the effectiveness of laser therapy for hypertrophic burn scars from this systematic 
review [60].
22.4 Silicone gel sheeting (SGS)
In 2006, a Cochrane review found weak evidence to support the use of SGS [61]. 
SGC was effective to reduce thickness, pain, itchiness, and pliability of hypertro-
phic scars in Chinese the population after 6 month’s intervention [62]. Silicone 
products, either in gel or sheet, are superior to onion extracts including heparin and 
allantoin in the treatment of the hypertrophic scar [63].
23. Invasive treatment
23.1 Intralesional corticosteroids
In patients with ongoing hypertrophy, more invasive measures are indicated. 
Intralesional corticosteroids is the only invasive option that has enough supporting 
evidence [64, 65]. The most commonly used is triamcinolone acetonide (TAC), the 
dose and treatment interval is variable ranging from 10 to 40 mg/ml given between 
2 and 4 weeks interval. The success rate is 50–100% in different studies with 9–50% 
experiencing recurrence [66, 67]. The TAC injection should be limited to the scar 
and avoid the periscar tissues. The adverse outcomes of skin atrophy, pigmentation, 
and telangiectasias are unacceptable by some patients [68–71].
The injection of TAC is not contraindicated in children, but that dose adaption 
to the child’s weight is advised to avoid systemic exposure [72, 73].
Additional injectable treatment options that may help to treat hypertrophic scars 
(and keloids) include 5-fluorouracil and verapamil.
23.2 5-Fluorouracil (5FU)
The use of antineoplastic agents as treatment options is logical because these 
abnormal tissues are in hypermetabolic states. 5-FU has been known to affect the 
fibroblast proliferation in tissue cultures because of its antimetabolite activity and 
has been shown to be an effective treatment for inflamed hypertrophic scars [28].
23.3 Triamcinolone acetonide and 5FU
This combination is associated with significantly greater reductions in scar 
size and erythema compared with triamcinolone acetonide alone in a 12-week 
Wound Healing
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double-blind study of 40 patients [74]. In a randomized control trial that include 
120, patients the mean reduction in scar height was significant in 5FU + TAC group 
versus TAC alone. Recurrence was seen in 39.2% of patients of the TAC group while 
in 17.5% of 5FU + TAC group (P = 0.012) [75].
Verapamil is a calcium channel antagonist that both decreases collagen syn-
thesis and increases collagen breakdown. In a randomized, single-blind study of 
54 patients with hypertrophic scars or keloids, scar vascularity, pliability, height, 
and width were reduced with intralesional verapamil, although the rate of reduc-
tion in these parameters was slower than with intralesional triamcinolone [76]. 
A randomized controlled of 50 patients the VSS scores were achieved with no 
therapeutic event or significant improvement was seen in verapamil group versus 
TAC group [77].
Pruritus is a chronic problem associated with many hypertrophic scars. Besides 
the emollient creams mentioned above, the use of local or systemic antihistamines 
may be useful and depends on the total body surface area involved in the areas of 
Figure 3. 
Release of first interdigital space with flap based on perforating of digital artery of index finger.
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itchiness. Some early evidence suggests that naltrexone may be a useful treatment 
for burn-related itching [78].
23.4 Surgical treatment
Surgical interventions for burn scars are usually postponed until the scar is 
considered “mature” or what may be 6–12 months after maturity, primarily because 
of the concern of recurrence of the scar. This may also have been influenced by burn 
scar reconstructive release surgeries performed by grafting and flaps. Most believe 
that the best option is the treatment with flaps [79] (Figures 3 and 4).
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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Figure 4. 
Multiple syndactyly release in a single time with seagull wings flap.
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